Bayer and Onyx's cancer treatment Nexavar has failed to show benefit in preventing the return of liver cancer after surgery. The drug is already approved in patients with hepatocellular carcinoma ...
The oncolytic virus therapy – also being developed by French biotech Transgene – failed to show any additional benefit when added to treatment with Bayer/Amgen’s targeted therapy Nexavar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback